TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12549799

Group type: EXPERIMENTAL
Intervention: Bifidobacteria Bb12 supplement
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Bifidobacteria Bb12 and Streptococcus thermophilus supplement
Number of subjects: 148

Group type: COMPARATOR
Intervention: Infant formula without supplement (Control)
Number of subjects: 148
Study: 9625220

Group type: EXPERIMENTAL
Intervention: 100 mg caffeine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 500 mg caffeine
Number of subjects: 21
Study: 7656463

Group type: EXPERIMENTAL
Intervention: Fasting followed by a one-year vegetarian diet
Number of subjects: 27

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 27
Study: 2658673

Group type: EXPERIMENTAL
Intervention: Intravenous analgosedation with midazolam (0.1 mg/kg) and fentanyl (2 micrograms/kg)
Number of subjects: 0
Study: 7454568

Group type: EXPERIMENTAL
Intervention: Ticlopidine HCl, 5-day course before surgery
Number of subjects: 0
Study: 31608962

Group type: EXPERIMENTAL
Intervention: Vi polysaccharide vaccine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Inactivated hepatitis A vaccine
Number of subjects: 80
Study: 30785903

Group type: EXPERIMENTAL
Intervention: Randomised response technique (RRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unmatched count technique (UCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nominative technique (NT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: False consensus bias (FCB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall prevalence of bear part use
Number of subjects: 0
Study: 28933576

Group type: EXPERIMENTAL
Intervention: Special training in recovery-oriented approach for mental health nurses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 26352252

Group type: EXPERIMENTAL
Intervention: 30-gauge needle for facial injections
Number of subjects: 20
Study: 24054381

Group type: EXPERIMENTAL
Intervention: Polypropylene mesh (PM) implant
Number of subjects: 100

Group type: COMPARATOR
Intervention: Anterior colporraphy with or without synthetic sling (Control)
Number of subjects: 100
Study: 21483004

Group type: EXPERIMENTAL
Intervention: docetaxel plus high-dose calcitriol (DN-101)
Number of subjects: 953

Group type: COMPARATOR
Intervention: docetaxel plus prednisone
Number of subjects: 953
Study: 19144565

Group type: EXPERIMENTAL
Intervention: CO(2) laser evoked potentials (LEPs) stimulation on the second and third fingers
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: CO(2) laser evoked potentials (LEPs) stimulation
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (sex- and age-matched subjects)
Number of subjects: 34
Study: 17723081

Group type: EXPERIMENTAL
Intervention: Concomitant ferrous sulfate with MMF (days -6 to 0)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dose-separated ferrous sulfate with MMF (days 9 to 16)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Polysaccharide iron complex with MMF (days -6 to 0)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Polysaccharide iron complex administered 2 hours after MMF (days 9 to 16)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control phase (MMF alone, days 1-8)
Number of subjects: 12
Study: 17011960

Group type: EXPERIMENTAL
Intervention: Tonosafe
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Tonojet
Number of subjects: 240

Group type: COMPARATOR
Intervention: Goldmann
Number of subjects: 240
Study: 12615629

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 39
Study: 10589629

Group type: EXPERIMENTAL
Intervention: 3.75 mg/mL ropivacaine
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 7.5 mg/mL ropivacaine
Number of subjects: 63

Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Piritramid (opioid)
Number of subjects: 63
Study: 8933852

Group type: EXPERIMENTAL
Intervention: Epidural infusion of alfentanil (0.75 mg bolus followed by 0.36 mg/h for 24 h)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous infusion of alfentanil (0.36 mg/h for 24 h)
Number of subjects: 20
Study: 1680361

Group type: COMPARATOR
Intervention: Fentanyl 7 micrograms kg‐1 followed by infusion of 3 micrograms kg‐1 h‐1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sufentanil 1 micrograms kg‐1 followed by 0.4 micrograms kg‐1 h‐1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both fentanyl and sufentanil
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fentanyl and Sufentanil
Number of subjects: 20
Study: 7088753

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antrafenine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29405923

Group type: EXPERIMENTAL
Intervention: Web-based mobile-supported cognitive-behavioral intervention
Number of subjects: 204

Group type: COMPARATOR
Intervention: Waitlist control condition with unrestricted access to usual care
Number of subjects: 204
Study: 27831985

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once daily
Number of subjects: 458

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 458
Study: 24218528

Group type: EXPERIMENTAL
Intervention: Rivastigmine (transdermal patch of 9.5 mg/day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 23076435

Group type: EXPERIMENTAL
Intervention: Freiburg monosyllabic test with hearing aids in background noise (CCITT-noise; 65/60 dB signal-noise ratio)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Freiburg monosyllabic test without hearing aids in background noise (CCITT-noise; 65/60 dB signal-noise ratio)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Freiburg monosyllabic test with hearing aids without background noise
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Freiburg monosyllabic test without hearing aids without background noise
Number of subjects: 217

Group type: COMPARATOR
Intervention: Freiburg monosyllabic test (control group)
Number of subjects: 217
Study: 20538557

Group type: EXPERIMENTAL
Intervention: 10 mg sibutramine once daily for 19 months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 15 mg sibutramine once daily for 19 months
Number of subjects: 60
Study: 18490787

Group type: EXPERIMENTAL
Intervention: athletic ability condition
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: technical soccer ability condition
Number of subjects: 51

Group type: COMPARATOR
Intervention: control condition
Number of subjects: 51
Study: 16291416

Group type: EXPERIMENTAL
Intervention: BIAsp 30 plus pioglitazone
Number of subjects: 281

Group type: COMPARATOR
Intervention: Glibenclamide plus pioglitazone
Number of subjects: 281

Group type: COMPARATOR
Intervention: BIAsp 30 monotherapy
Number of subjects: 281
Study: 12461758

Group type: EXPERIMENTAL
Intervention: Group-based 10-week strength training intervention (N=34)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Home exercise control (N=34)
Number of subjects: 68
Study: 10498359

Group type: EXPERIMENTAL
Intervention: Topical and subcutaneous epinephrine with bovine topical thrombin (1000 U/ml)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no epinephrine, only bovine topical thrombin)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study: 8983684

Group type: EXPERIMENTAL
Intervention: Dietary caffeine restriction
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Number of subjects: 13
Study: 2016228

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 7062378

Group type: EXPERIMENTAL
Intervention: Continuous flow resectoscope
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional resectoscope
Number of subjects: 36
Study: 31835040

Group type: EXPERIMENTAL
Intervention: Endostatin (highest quartile)
Number of subjects: 3463

Group type: EXPERIMENTAL
Intervention: Endostatin (1-SD higher log-transformed)
Number of subjects: 3463

Group type: EXPERIMENTAL
Intervention: Endostatin (added to basic model)
Number of subjects: 3463
Study: 30829203

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Anti‐tuberculosis regime (Control)
Number of subjects: 80
Study: 28266591

Group type: EXPERIMENTAL
Intervention: Aggressive hydration (20 ml/kg bolus followed by 3 ml/kg/h)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard hydration (10 ml/kg bolus followed by 1.5 ml/kg/h)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aggressive hydration
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard hydration
Number of subjects: 60
Study: 25864739

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) at 0.067 mg/kg/day
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 24007461

Group type: EXPERIMENTAL
Intervention: Group 2 (from <5 mg/L to ≥5 mg/L, n = 45)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Group 4 (from ≥5 mg/L to ≥5 mg/L, n = 80)
Number of subjects: 327
Study: 21411210

Group type: EXPERIMENTAL
Intervention: Motiva System with educational videos, motivational messages, and questionnaires
Number of subjects: 92

Group type: COMPARATOR
Intervention: Motiva System + self monitoring of blood pressure, heart rate, and weight
Number of subjects: 92
Study: 19288937

Group type: EXPERIMENTAL
Intervention: Stented group (11 patients)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Stentless group (27 patients)
Number of subjects: 38
Study: 17291934

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study: 12875938

Group type: COMPARATOR
Intervention: Intrarectal lidocaine gel (10 cc of 2% lidocaine gel)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Periprostatic nerve block (10 cc of 1% lidocaine solution injected under ultrasound guidance)
Number of subjects: 96
Study: 10730921

Group type: EXPERIMENTAL
Intervention: Pear juice
Number of subjects: 39

Group type: COMPARATOR
Intervention: Grape juice
Number of subjects: 39
Study: 9344323

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy with DOX/DDP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histological response to neoadjuvant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Change of chemotherapy for poor histological response
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased dose intensity with G-CSF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incorporation of new agents like Ifosfamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various drug administration methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rosen T10 protocol
Number of subjects: 0
Study: 1314711

Group type: EXPERIMENTAL
Intervention: One dose of trivalent oral poliovirus vaccine (TOPV) at birth and subsequent doses at 2, 4, and 9 months of age (Group A)
Number of subjects: 85

Group type: COMPARATOR
Intervention: One dose of trivalent oral poliovirus vaccine (TOPV) at 2, 4, and 6 months of age (Group B)
Number of subjects: 85
Study: 3905062

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 686

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 686
Study: 31295854

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Central European diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher energy intake from fat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GG IL6 rs1800795 genotype
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C-allele carriers of IL6 rs1800795
Number of subjects: 0

Group type: COMPARATOR
Intervention: IL6 gene transcription levels and blood IL6 concentrations
Number of subjects: 0
Study: 28145999

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 25900227

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.1 μg/kg/min infusion
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.3 μg/kg/min infusion
Number of subjects: 90
Study: 23407306

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (4000 IU/d)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 21124330

Group type: EXPERIMENTAL
Intervention: Benidipine (2 mg/day increased to 8 mg/day)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Amlodipine (2.5 mg/day increased to 10 mg/day)
Number of subjects: 104
Study: 20008241

Group type: EXPERIMENTAL
Intervention: MP plus thalidomide (MPT)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: MP plus bortezomib (MPV)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: MP plus lenalidomide or lenalidomide plus dexamethasone
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Combination of cyclophosphamide, thalidomide, and dexamethasone
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Reduced-intensity transplantation
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Standard MPT or MPV with reduced doses
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Accurate management of treatment-related adverse events
Number of subjects: 5
Study: 17996133

Group type: EXPERIMENTAL
Intervention: Potassium magnesium aspartate
Number of subjects: 98

Group type: COMPARATOR
Intervention: Routine therapy for coronary heart disease (Control)
Number of subjects: 98
Study: 15485433

Group type: EXPERIMENTAL
Intervention: Solid 8‐mm‐tip catheter (group A, 65 degrees C, 70 W, 60 s)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Open irrigated‐tip catheter (group B, 65 degrees C, 50 W, 60 s, 17 mL/min flow)
Number of subjects: 130
Study: 11508714

Group type: EXPERIMENTAL
Intervention: Trace discrimination conditioning (500 ms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trace discrimination conditioning (1000 ms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delay discrimination conditioning (750 ms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delay discrimination conditioning (1250 ms)
Number of subjects: 0
Study: 9704873

Group type: EXPERIMENTAL
Intervention: moclobemide (450 mg/day)
Number of subjects: 124

Group type: COMPARATOR
Intervention: clomipramine (150 mg/day)
Number of subjects: 124
Study: 7626576

Group type: EXPERIMENTAL
Intervention: Unilateral occlusion for 1 hour per day for 4 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Unilateral occlusion for 4 hours per day for 4 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Unilateral occlusion for 8 hours per day for 4 weeks
Number of subjects: 15
Study: 2926470

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide plus cisplatin (CP)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Cyclophosphamide plus cisplatin plus doxorubicin (CAP)
Number of subjects: 349
Study: 82680

Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g/day) for 3, 6, 9, or 12 months
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g/day)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g/day) for 1 year
Number of subjects: 96
Study: 31409579

Group type: EXPERIMENTAL
Intervention: NER1006 (1L polyethylene glycol)
Number of subjects: 1378

Group type: COMPARATOR
Intervention: 2L polyethylene glycol + ascorbate (2LPEG)
Number of subjects: 1378

Group type: COMPARATOR
Intervention: Oral sulfate solution (OSS)
Number of subjects: 1378
Study: 27922948

Group type: EXPERIMENTAL
Intervention: Fluoroscopic guidance
Number of subjects: 100

Group type: COMPARATOR
Intervention: Loss of resistance with saline/air
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Correctly positioned thoracic epidural catheters
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 24-hour morphine use
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 24-hour numeric pain scores
Number of subjects: 100
Study: 25524834

Group type: EXPERIMENTAL
Intervention: Boceprevir (BOC)
Number of subjects: 2288

Group type: EXPERIMENTAL
Intervention: Telaprevir (TPV)
Number of subjects: 2288

Group type: COMPARATOR
Intervention: PEG/RBV (Control)
Number of subjects: 2288
Study: 23233710

Group type: EXPERIMENTAL
Intervention: CHOP plus rituximab (CHOP-R)
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: CHOP chemotherapy plus iodine-131 tositumomab (CHOP-RIT)
Number of subjects: 554
Study: 20933046

Group type: EXPERIMENTAL
Intervention: Fissure sealant applied to alternate teeth
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control teeth (uncoated)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Comparison of sealed vs control teeth at final visit
Number of subjects: 17
Study: 20141067

Group type: EXPERIMENTAL
Intervention: Lateral internal sphincterotomy (group S)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Local diltiazem ointment (group D)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Local glyceryl trinitrate ointment (group GTN)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Injection of botulinum toxin (group BT)
Number of subjects: 160
Study: 16769462

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 136

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 136
Study: 12945826

Group type: EXPERIMENTAL
Intervention: Coding by experienced dietitians using the same database and software package
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Coding by experienced dietitians
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Analysis of nutrients (e.g., vitamin C, vitamin A, cholesterol)
Number of subjects: 52
Study: 10532600

Group type: EXPERIMENTAL
Intervention: RBC transfusions if Hb < 8 g/dL or predetermined clinical conditions
Number of subjects: 428

Group type: COMPARATOR
Intervention: Control group treated according to physician's orders (Hb < 9 g/dL)
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 428
Study: 8955546

Group type: EXPERIMENTAL
Intervention: Physical activation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rest
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Major depression
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 1867151

Group type: EXPERIMENTAL
Intervention: 10 weeks of friendly staff telephone contact
Number of subjects: 0

Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuation of staff contact
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peer telephone dyads
Number of subjects: 0
Study: 7080769

Group type: EXPERIMENTAL
Intervention: Inactivated chromatographic influenza vaccine A(H3N2)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 3858877

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study: 29308962

Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (untaped patients)
Number of subjects: 39
Study: 26510183

Group type: EXPERIMENTAL
Intervention: Patient-Controlled Epidural Analgesia (PCEA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Patient-Controlled Intravenous Analgesia (PCIA)
Number of subjects: 120
Study: 24767719

Group type: EXPERIMENTAL
Intervention: 6-day course of daily prednisolone therapy during an upper respiratory tract infection (URTI)
Number of subjects: 300

Group type: COMPARATOR
Intervention: No change to current therapy (placebo)
Number of subjects: 300
Study: 22002685

Group type: EXPERIMENTAL
Intervention: Alfalfa (ALF)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Birdsfoot trefoil (BFT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (TF or RCG without ALF or BFT)
Number of subjects: 20
Study: 20438325

Group type: EXPERIMENTAL
Intervention: Tart cherry juice beverage (CherryPharm, Inc.)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 15
Study: 18519476

Group type: EXPERIMENTAL
Intervention: 100% oxygen
Number of subjects: 41

Group type: COMPARATOR
Intervention: Room air (21% oxygen)
Number of subjects: 41
Study: 15783019

Group type: EXPERIMENTAL
Intervention: Dai-kenchu-to (DKT) 5g administered orally three times a day
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Lactulose 16g administered orally three times a day
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 84
Study: 12689357

Group type: EXPERIMENTAL
Intervention: Lumbar skin warming (42 degrees C, 20 min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Time-matched control group without skin warming
Number of subjects: 0
Study: 10532092

Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg once daily
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Letrozole 0.5 mg once daily
Number of subjects: 555

Group type: COMPARATOR
Intervention: Aminoglutethimide (AG) 250 mg twice daily with corticosteroid support
Number of subjects: 555
Study: 8530996

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation not modified and local tranexamic acid applied during and after surgery
Number of subjects: 92

Group type: COMPARATOR
Intervention: Oral anticoagulation reduced and calcium heparin added preoperatively
Number of subjects: 92
Study: 1991755

Group type: EXPERIMENTAL
Intervention: Hansson pin technique
Number of subjects: 115

Group type: COMPARATOR
Intervention: Uppsala screw technique
Number of subjects: 115
Study: 7113711

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg (D)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Alcohol 0.5 g/kg (A)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg (D) + Alcohol 0.5 g/kg (A)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 31239180

Group type: EXPERIMENTAL
Intervention: Patient-centered consultations
Number of subjects: 97

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 97
Study: 29417169

Group type: EXPERIMENTAL
Intervention: TEA (transepicondylar axis)
Number of subjects: 48

Group type: COMPARATOR
Intervention: PoCoLi (posterior condylar line)
Number of subjects: 48